For 50 years Western governments have relentlessly undermined the mental health of their citizens while also criminalizing the only effective drugs for treating mental health.
Psychedelics
PharmaTher Announces Positive Topline Results from Clinical Study of Ketamine for Parkinson’s Disease
Pharmather reports positive tolerability and dose-finding results in its clinical trial of a ketamine-based drug for Parkinson's disease as it prepares for a Phase III trial.
Awakn Life Sciences Announces Closing of Private Placement
Awakn Life Sciences announces closing a a CAD $3.25 million private placement, with units priced at $1.60 along with a half-warrant with an exercise price of $2.20.
Wesana Health Announces New Findings Indicating Psilocybin Potentiates Impact of an Anti-Depressant
Wesana Health reports positive treatment results in combining traditional antidepressants with psilocybin-based therapy.
Revitalist Launches UNIT Initiative Working With Veteran and First Responder Non-Profits Across the United States Creating Nationwide Guidelines
Revitalist Lifestyle and Wellness announces a new initiative focusing on providing access to mental health therapies for veterans and first-responders.
Red Light Holland Successfully Imports Psilocybin iMicrodose Packs into St. Vincent and the Grenadines Under a First-Ever Authorized Import Approval Process by the Country's Bureau of Standards and the Ministry of Health
Red Light Holland announces the first-ever import of psilocybin mushrooms into St. Vincent and the Grenadines.
Awakn Life Sciences Receives Regulatory Approval for Flagship Clinic in London to Begin Delivering Treatments
Awaken receives regulatory approval to begin ketamine-based therapies in its flagship London mental health clinic.
MINDCURE Provides Update on Strategic Review
MINDCURE announces the completion of its strategic review and new cost saving measures.
Ketamine Wellness Centers (KWC) Announces Grand Opening of Reno Clinic
Ketamine Wellness Centers, a subsidiary of Delic Holdings, announces the grand opening of its 13th ketamine clinic.
Novamind to Host MindMed Phase IIb Trial for LSD and Anxiety
Novamind announces it will most MindMed's Phase IIb clinical trial of LSD-based therapy for generalized anxiety disorder (GAD).
Brain Injury Awareness Month: New Hope With Psychedelic Medicine
Thanks to the advance of psychedelic medicine, "brain injury awareness" is about more than highlighting a problem. It's also about new hope for sufferers.
Enveric Biosciences Announces Publication of Four Patent Applications for Psychedelic-Inspired Drug Candidates
Enveric Bioscience announces the publishing of four PCT applications by the World Intellectual Property Organization.
Wesana Health Announces Positive Feedback From Pre-IND Meeting With FDA on SANA-013
Wesana Health reports positive feedback from FDA on pre-IND meeting regarding development of SANA -013 and is anticipating commencing a clinical trial in Q4 2022.
Bright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial
Bright Minds Biosciences announced the successful completion of a 28-day toxicology study for BMB-101.
Numinus Expands Natural Psychedelic Research with New Biosecurity License
Numinus announces that its Numinus Bioscience research lab has been approved for a Containment Level 2 (CL2) license from Health Canada.